With multiple antigen epitopes for patients with glioblastoma, neoantigen-specific CD4+ and CD8+ T cells from the peripheral blood could infiltrate into intracranial glioblastoma in patients, paving a new avenue for immunotherapy targeting glioblastoma TME [108]. This evidence concerns the gene CD8A and glioblastoma.